Company intelligence / Profile preview

Chimerna Therapeutics

New York City, New York, USAchimerna.com ↗

Ownership: Private
Employees: ~10
Development stage: Preclinical

Overview

Chimerna Therapeutics is developing a proprietary circular RNA technology to address the limitations of traditional linear RNA therapeutics, focusing on improved stability and abundance. Their preclinical pipeline targets previously untreatable diseases such as ADPKD, Alzheimer’s, and Parkinson's. The company also offers high-throughput screening technologies for microRNA target identification and depletion but has not yet advanced programs into clinical trials.

Therapeutic areas: NeurologyNephrology
Modalities: Circular RNA (circRNA)RNA aptamersMolecular spongesProtein expression via RNAMolecular sensors
Industry: Biotech

Beyond the preview

Go deeper on Chimerna Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chimerna Therapeutics.

Explore the full profile